InventisBio Co Ltd
688382
Company Profile
Business description
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
Contact
No. 4, Lane 67, Li Bing Road
Room 210
Pilot Free Trade Zone
Shanghai201203
CHNT: +86 2150778527
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
182
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,271.65 | 27.36 | 0.33% |
| DAX 40 | 24,935.50 | 9.45 | -0.04% |
| Dow JONES (US) | 51,561.93 | 874.86 | 1.73% |
| FTSE 100 | 10,394.14 | 33.82 | 0.33% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 26,830.96 | 23.02 | -0.09% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,584.31 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |